ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) — GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 975,610 shares of the Company’s common stock (or common stock equivalents) at a price of $5.125 per share in a registered direct offering priced at-the-market under Nasdaq rules.
GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Latest posts by GlobeNewswire (see all)
- Advantest to Showcase IC Test Solutions at Inaugural SEMICON India, Sept. 11-13, 2024 in Greater Noida - September 10, 2024
- IoT Chipset Market to cross USD 750 Billion by 2032, Says Global Market Insights inc. - September 10, 2024
- NXP Combines Ultra-Wideband Secure Ranging and Short-Range Radar to Enable Autonomous Industrial and IoT Applications - September 10, 2024
